DPhil

1. 2026 Raman Group: Pioneering Precision Medicine in Hypertrophic Cardiomyopathy: Advanced Imaging, Machine Learning, and Translational Research for Early Detection and Targeted Therapies — Radcliffe Department of Medicine
   
2. 2026 Raman Group (MRC Enterprise iCase): Development of Cardiac Diffusion Tensor Imaging for Clinical Evaluation of Cardiomyopathies — Radcliffe Department of Medicine
   

MSc by Research

1. Raman Group: Intergrating Multimodal Imaging, Genomics, and Clinical Data for Risk Stratification and Precision Therapy in Cardiomyopathies through Novel Artificial Intelligence Approaches — Radcliffe Department of Medicine
   
2. Raman Group: Multi-Organ MRI Phenotyping for Risk Prediction in Heart Failure and Multisystem Diseases: Insights from Prospective Imaging Cohorts and UK Biobank — Radcliffe Department of Medicine
3. Raman Group: AI-Enhanced ECG and Digital Twin Modelling for Early Diagnosis and Mechanistic Stratification in Cardiomyopathies — Radcliffe Department of Medicine
   
4. Raman Group: Unravelling Mechanisms of Phenotypic Diversity in Hypertrophic Cardiomyopathy through Advanced Cardiac MRI and Patient-Specific Multi-Omic Modelling — Radcliffe Department of Medicine
   
5. Raman Group: Enhancing Traditional and Photon-Counting CT for the Early Diagnosis and Phenotyping of Cardiomyopathies — Radcliffe Department of Medicine

I am a senior clinical academic cardiologist specialising in advanced cardiovascular imaging (CMR and Cardiac CT) and inherited and cardiomyopathic heart disease, leading a translational research programme that bridges mechanistic discovery, clinical application, and innovation in drug development.

 After completing specialist training in cardiology in Australia (FRACP), I joined the University of Oxford in 2015 to pursue a DPhil in Hypertrophic Cardiomyopathy (HCM)-the leading cause of sudden cardiac death in young adults and athletes. My doctoral work led to the development of a novel oxygen-sensitive magnetic resonance method that detects myocardial hypoxia non-invasively and holds promise as an early biomarker of disease activity. This pioneering work has been recognised internationally (ESC, AHA, BSCMR, SCMR, and BCS awards).

 Building on this foundation, I was awarded a British Heart Foundation Transition Fellowship (2020) and subsequently a Wellcome Career Development Award (2024) to advance a multi-disciplinary programme integrating imaging, genetics, energetics, and computational modelling. My goal is to identify and validate early markers of disease progression in HCM and related cardiomyopathies, enabling more precise risk prediction and accelerating evaluation of emerging therapies.

During the COVID-19 pandemic, I led the C-MORE study, a large multi-centre initiative that combined MRI, cardiopulmonary exercise testing, and cognitive assessments to characterise the long-term, multi-organ consequences of COVID-19. This work helped shape understanding of post-viral cardiovascular and systemic recovery.

My current research focuses on:

1)    Early-stage disease detection and monitoring in cardiomyopathies using next-generation CMR (BOLD, DTI, spectroscopy, radiomics).

2)    Mechanistic biomarkers to support early-phase and adaptive clinical trials. 

3)    Cross-organ interactions in cardiometabolic disease, integrating heart-brain-liver-renal imaging.

As a senior academic leader, I collaborate widely across academia, the NHS, and industry to translate advanced imaging into clinical and commercial impact. I actively welcome scientific collaborators, students, and industrial partners interested in biomarker discovery, imaging-enabled trial design, and AI-based modelling for cardiovascular disease.